Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: January 2010
-
By Donald Zuhn — BIO CEO Asks President to Focus on Unresolved Issues in Health Care Debate Writing for True/Slant earlier this month, Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood provided his organization's take on recent efforts by President Obama to re-write the biosimilars provisions of the House and Senate health care…
-
February 4, 2010 – "Are Genes Patentable?" (Intellectual Property Litigation Committee, American Bar Association) – Chicago February 4, 2010 – Bay Area Pharma and Life Sciences IP Summit (Fish & Richardson and Berkeley Center for Law & Technology) – San Mateo, CA February 9, 2010 – Patent Prosecution: Best Practices for Reducing Costs While Improving…
-
By Christopher P. Singer — In a January 15, 2010 press release, the U.S. Patent and Trademark Office announced three new members to the Patent Public Advisory Committee (PPAC) and two new members to the Trademark Public Advisory Committee (TPAC), as named by Commerce Secretary Locke. The Public Advisory Committees for the USPTO, which…
-
Technology Transfer Tactics will be offering an audioconference entitled "The Bilski Decision: Expert Strategies to Manage Its Impact on University IP" on March 30, 2010 from 1:00 – 2:30 PM (EST). Patent Docs author Dr. Kevin Noonan, a partner at McDonnell Boehnen Hulbert & Berghoff LLP; Dr. Jim Baker, Director of Technology and Economic Development…
-
The American Bar Association (ABA) Section of Intellectual Property Law will be holding the 25th Annual Intellectual Property Law Conference on April 7-10, 2010 in Arlington, VA. Among the topics that will be covered at the conference are: • Patent reform legislation — Where we are, how did we get here, and what does the…
-
By Donald Zuhn — In a press release issued today, the U.S. Patent and Trademark Office announced that it would be implementing an interim procedure by which patentees can request Patent Term Adjustment (PTA) recalculations while the Office revises its procedures to comply with the Federal Circuit's decision in Wyeth v. Kappos. In Wyeth,…
-
By Suresh Pillai — Mylan and Matrix Fail in Bid to Dismiss Sustiva® Case The U.S. District Court for the District of Delaware has ruled that Bristol-Myers Squibb may proceed with its patent infringement suit against defendants Mylan Pharmaceuticals and Matrix Laboratories over Bristol-Myers' patent covering the HIV treatment Sustiva®, U.S. Patent No. 6,673,372. …
-
By James DeGiulio — Earlier this month, we reported on a study published last year in the The Columbia Science and Technology Law Review, which suggested a commons systems can generate significantly greater amounts of innovation, productivity, and social utility than currently predominating patent systems that combine both patent and open source protection for…
-
The Metes and Bounds of Obviousness-type Double Patenting By Kevin E. Noonan — Obvious-type double patenting has become an important issue in patent litigation (Amgen Inc. v. F. Hoffman-La Roche Ltd., Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., Proctor & Gamble Co. v. Teva Pharmaceuticals USA, Inc.) and in the Patent Office (In re…
-
By Donald Zuhn — In a paper published earlier this month, David Adelman and Christopher Holman assert that in the debate on follow-on biologics legislation, "the controversy over regulatory 'data exclusivity' is a sideshow." The authors argue that policymakers should instead "focus on mitigating the systemic barriers to entry that pose much greater and…
Patent Docs 